Journal of Traditional Medical Complementary Therapies

.: REVIEW
İnek Sütü ve Prostat Kanseri İlişkisi
The Relationship Between Cow Milk and Prostate Cancer
Tuğba KAHVECİOĞLUa, Fatma Esra GÜNEŞa
aBeslenme ve Diyetetik Bölümü, Marmara Üniversitesi Sağlık Bilimleri Fakültesi, İstanbul, TÜRKİYE
J Tradit Complem Med. 2019;2(3):160-8
doi: 10.5336/jtracom.2019-70727
Article Language: TR
Full Text
ÖZET
 Prostat kanseri, prostat bezinin herhangi bir yerinde başlayabilen, ilk 5-10 yılında yavaş, sonra hızla büyüyen ve diğer organlara yayılabilen tedavi edilmesi güç bir hastalıktır. Türkiye'de 2014 yılında erkeklerde en sık görülen 10 kanser sıralamasında akciğer kanserini takiben ikinci sıraya yerleşen prostat kanseri, tüm yaş grupları sıralamasında da ikinci sırada yer almaktadır. Bu derlemede, prostat kanserli bireylerin inek sütü tüketiminin hastalığın seyrine olan etkisi ve inek sütünün kanser hücre gelişimi üzerine etkisini açıklamak amaçlanmıştır. Bunun yanında, prostat kanseri görülme sıklığı ve ölüm oranı ile ne kadar ilişkili olabileceği sorgulanmıştır. Süt tüketimi ve prostat kanseri ile ilişkili olduğu düşünülen muhtemel mekanizmalardan kalsiyum, insülin benzeri büyüme faktörü, DNA metiltransferaz 1 sinyalini zayıflatan süt kaynaklı mikroRNA'lar ve yüksek inek sütü tüketimi ile artan mTORC1 sinyalizasyonu açıklanmıştır. Güncel sonuçlar çocukluk dönemindeki süt tüketimini prostat kanseri riski ile ilişkili görmeyip, erişkinlikteki süt tüketiminin biyolojik bir temeli olabileceğine işaret etmektedir. Dünya Kanser Araştırma Fonu'nda süt ve süt ürünleri üzerine mevcut kanıtlar sınırlı olarak raporlanıp, süt ve süt ürünlerinin prostat kanseri risk artışına neden olduğuna vurgu yapılmıştır. İnek sütündeki mikroRNA'ların insan besin zincirinden çıkarılması, prostat gelişimi ve farklılaşmasının mTORC1'e bağlı gerçekleşen fazları sırasında inek sütü alımının kısıtlanması ve mTORC1 sinyallerini zayıflatıcı yönde diyet müdahaleleri prostat kanserinden korunma amaçlı girişimler olarak uygulanabilir.

Anahtar Kelimeler: Prostat kanseri; süt; diyet; besin ve beslenme
ABSTRACT
 Prostate cancer is a difficult disease that is slowly grow in the first 5-10 years that can start any part of the prostate gland, then grow rapidly and spread to other organs. In 2014 the 10 most common male cancer in Turkey ranking of prostate cancer into second place after lung cancer, it is in second place in the ranking of all age groups. In this review, it is aimed to explain the effect of cow milk consumption on the course of disease and the effect of cancer cell development. In addition, the relationship between the incidence of prostate cancer and the mortality rate were questioned. Potentially thought to be related to milk-prostate cancer, calcium, insulin-like growth factor, milk-induced miRNAs that weaken the DNA methyltransferase 1 signal, and increased mTORC1 signaling with high cow milk consumption have been described. Recent results suggest that milk consumption in childhood is not associated with prostate cancer risk, and that milk consumption in adulthood may have a biological basis. According to the World Cancer Research Fund, evidence on milk and dairy products has been reported as limited-thought-provoking and emphasized that milk and dairy products cause an increased risk of prostate cancer. Removal of miRNAs from cow's milk from the human food chain, restriction of cow's milk intake during mTORC1-dependent phases of prostate development and differentiation, and dietary interventions in the direction of attenuating mTORC1 signals can be applied as prophylaxis of prostate cancer prevention.

Keywords: Prostate cancer; milk; diet; food and nutrition
REFERENCES:
  1. Baysal A, Criss W. [Kanser Türleri Hakkında Bilmemiz Gerekenler]. Kanseri Tanıyalım.
  2. Baskı. Ankara: Hatiboğlu Basın ve Yayım San. Tic. Ltd. Şti; 2004. p.65-6.
  3. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. Türkiye Kanser İstatistikleri. Ankara: 2017. p.47. Available from: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/2014-RAPOR._uzuuun.pdf. Accessed: April 14,2019.
  4. Türkiye İstatistik Kurumu (TÜİK). Ölüm Nedeni İstatistikleri 2017. Available from: http://tuik.gov.tr/PreTablo.do?alt_id=1083. Accessed: April 14,2019.
  5. Mandair D, Rossi RE, Pericleous M, Whyand T, Caplin ME. Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr Metab (Lond). 2014,11:30. [Crossref]  [PubMed]  [PMC] 
  6. Ünal RN, Besler HT. T.C. Sağlık Bakanlığı. Beslenmede Sütün Önemi. Sağlık Bakanlığı Yayın No: 727. 1. Baskı. Ankara: Klasmat Matbaacılık; 2008. p.29. Available from: http://sbu.saglik.gov.tr/ekutuphane/kitaplar/b%208.pdf Accessed: April 14,2019.
  7. Stoops EH, Caplan MJ. Trafficking to the apical and basolateral membranes in polarized epithelial cells. J Am Soc Nephrol. 2014;25(7):1375-86. [Crossref]  [PubMed]  [PMC] 
  8. Kuokkanen M, Enattah NS, Oksanen A, Savilahti E, Orpana A, Järvelä I. Transcriptional regulation of the lactase-phlorizin hydrolase gene by polymorphisms associated with adult-type hypolactasia. Gut. 2003;52(5):647-52. [Crossref]  [PubMed]  [PMC] 
  9. Travis RC, Appleby PN, Siddiq A, Allen NE, Kaaks R, Canzian F, et al. Genetic variation in the lactase gene, dairy product intake and risk for prostate cancer in the European prospective investigation into cancer and nutrition. Int J Cancer. 2013;132(8):1901-10. [Crossref]  [PubMed]  [PMC] 
  10. Nielsen T, Höjer A, Gustavsson AM, Hansen-Møller J, Purup S. Proliferative effect of whey from cows' milk varying in phyto-oestrogens in human breast and prostate cancer cells. J Dairy Res. 2012;79(2):143-9. [Crossref]  [PubMed] 
  11. Elzoghby AO, El-Fotoh WS, Elgindy NA. Casein-based formulations as promising controlled release drug delivery systems. J Control Release. 2011;153(3):206-16. [Crossref]  [PubMed] 
  12. Park SW, Kim JY, Kim YS, Lee SJ, Lee SD, Chung MK. A milk protein, casein, as a proliferation promoting factor in prostate cancer cells. World J Mens Health. 2014;32(2):76-82. [Crossref]  [PubMed]  [PMC] 
  13. Soki FN, Koh AJ, Jones JD, Kim YW, Dai J, Keller ET, et al. Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem. 2014;289(35):24560-72. [Crossref]  [PubMed]  [PMC] 
  14. Bernichtein S, Pigat N, Capiod T, Boutillon F, Verkarre V, Camparo P, et al. High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions. PLoS One. 2015;10(5):e0125423. [Crossref]  [PubMed]  [PMC] 
  15. Deneo-Pellegrini H, Ronco AL, De Stefani E, Boffetta P, Correa P, Mendilaharsu M, et al. Food groups and risk of prostate cancer: a case-control study in Uruguay. Cancer Causes Control. 2012;23(7):1031-8. [Crossref]  [PubMed] 
  16. Song Y, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, et al. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr. 2013;143(2):189-96. [Crossref]  [PubMed]  [PMC] 
  17. Downer MK, Batista JL, Mucci LA, Stampfer MJ, Epstein MM, Håkansson N, et al. Dairy intake in relation to prostate cancer survival. Int J Cancer. 2017;140(9):2060-9. [Crossref]  [PubMed] 
  18. Lu W, Chen H, Niu Y, Wu H, Xia D, Wu Y. Dairy products intake and cancer mortality risk: a meta-analysis of 11 population-based cohort studies. Nutr J. 2016;15(1):91. [Crossref]  [PubMed]  [PMC] 
  19. Tat D, Kenfield SA, Cowan JE, Broering JM, Carroll PR, Van Blarigan EL, et al. Milk and other dairy foods in relation to prostate cancer recurrence: data from the cancer of the prostate strategic urologic research endeavor (CaPSURE?). Prostate. 2017;78(1):32-9. [Crossref]  [PubMed]  [PMC] 
  20. World Cancer Research Fund: Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. London: World Cancer Research Fund; 2007. Available at: https://www.wcrf.org/sites/default/files/english.pdf. Accessed April 14,2019.
  21. Ma RW, Chapman K. A systematic review of the effect of diet in prostate cancer prevention and treatment. J Hum Nutr Diet. 2009;22(3):187-99. [Crossref]  [PubMed] 
  22. Steck SE, Omofuma OO, Su LJ, Maise AA, Woloszynska-Read A, Johnson CZ, et al. Calcium, magnesium, and whole-milk intakes and high-aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Am J Clin Nutr. 2018;107(5):799-807. [Crossref]  [PubMed] 
  23. Aune D, Navarro Rosenblatt DA, Chan DS, Vieira AR, Vieira R, Greenwood DC, et al. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr. 2015;101(1):87-117. [Crossref]  [PubMed] 
  24. Harrison S, Lennon R, Holly J, Higgins J, Gardner M, Perks C, et al. Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis. Cancer Causes Control. 2017;28(6):497-528. [Crossref]  [PubMed]  [PMC] 
  25. Lee J, Ju J, Park S, Hong SJ, Yoon S. Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of β-catenin signaling in hormone refractory PC-3 prostate cancer cells. Nutr Cancer. 2012;64(1):153-62. [Crossref]  [PubMed] 
  26. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Moorthy S, et al. Combined inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One. 2012;7(12):e51189. [Crossref]  [PubMed]  [PMC] 
  27. Rani P, Vashisht M, Golla N, Shandilya S, Onteru SK, Singh D. Milk miRNAs encapsulated in exosomes are stable to human digestion and permeable to intestinal barrier in vitro. J Funct Foods. 2017;34:431-9. [Crossref] 
  28. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15-6 [Crossref]  [PubMed] 
  29. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci U S A. 2002;99(13):8467-72. [Crossref]  [PubMed]  [PMC] 
  30. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943-56. [Crossref]  [PubMed]  [PMC] 
  31. Liu J, Zhang C, Zhao Y, Feng Z. MicroRNA control of p53. J Cell Biochem. 2017;118(1):7-14. [Crossref]  [PubMed] 
  32. Golan-Gerstl R, Elbaum-Shiff Y, Moshayoff V, Schester D, Leshkowitz D, Reif S. Characterization and biological function of milk-derived miRNAs. Mol Nutr Food Res. 2017;61(10). [Crossref]  [PubMed] 
  33. Culotta E, Koshland DE Jr. p53 sweeps through cancer research. Science. 1993;262(5142):1958-61. [Crossref]  [PubMed] 
  34. Li E, Zhang Y. DNA methylation in mammals. Cold Spring Harb Perspect Biol. 2014;6(5):a019133. [Crossref]  [PubMed]  [PMC] 
  35. Lee E, Wang J, Yumoto K, Jung Y, Cackowski FC, Decker AM, et al. DNMT1 regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis. Neoplasia. 2016;18(9):553-66. [Crossref]  [PubMed]  [PMC] 
  36. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277(5):3247-57. [Crossref]  [PubMed] 
  37. Melnik BC. Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer. Nutr Metab (Lond). 2017;14:55. [Crossref]  [PubMed]  [PMC] 
  38. Rich-Edwards JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Tserendolgor U, et al. Milk consumption and the prepubertal somatotropic axis. Nutr J. 2007;6:28. [Crossref]  [PubMed]  [PMC] 
  39. Qin LQ, He K, Xu JY. Milk consumption and circulating insulin-like growth factor-I level: a systematic literature review. Int J Food Sci Nutr. 2009;60 Suppl 7:330-40. [Crossref]  [PubMed] 
  40. Melnik B. Dietary intervention in acne: attenuation of increased mTORC1 signaling promoted by Western diet. Dermatoendocrinol. 2012;4(1):20-32. [Crossref]  [PubMed]  [PMC] 
  41. Inoki K, Ouyang H, Li Y, Guan KL. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev. 2005;69(1):79-100. [Crossref]  [PubMed]  [PMC] 
  42. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell. 2007;12(4):487-502. [Crossref]  [PubMed] 
  43. Wang X, Proud CG. Nutrient control of TORC1, a cell-cycle regulator. Trends Cell Biol. 2009;19(6):260-7. [Crossref]  [PubMed] 
  44. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310-22. [Crossref]  [PubMed]  [PMC] 
  45. Suzuki T, Inoki K. Spatial regulation of the mTORC1 system in amino acids sensing pathway. Acta Biochim Biophys Sin (Shanghai). 2011;43(9):671-9. [Crossref]  [PubMed]  [PMC] 
  46. Wang X, Proud CG. mTORC1 signaling: what we still don't know. J Mol Cell Biol. 2011;3(4):206-20. [Crossref]  [PubMed] 
  47. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22. [Crossref]  [PubMed]  [PMC] 
  48. Melnik BC, John SM, Carrera-Bastos P, Cordain L. The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr Metab (Lond). 2012;9(1):74. [Crossref]  [PubMed]  [PMC] 
  49. Manders RJ, Prate SF, Meex RC, Koopman R, de Roos AL, Wagenmakers AJ, et al. Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. Diabetes Care. 2006;29(12):2721-2. [Crossref]  [PubMed] 
  50. Hoppe C, Mølgaard C, Juul A, Michaelsen KF. High intakes of skimmed milk, but not meat, increase serum IGF-I and IGFBP-3 in eight-year-old boys. Eur J Clin Nutr. 2004;58(9):1211-6. [Crossref]  [PubMed] 
  51. Hoppe C, Mølgaard C, Vaag A, Barkholt V, Michaelsen KF. High intakes of milk, but not meat, increase s-insulin and insulin resistance in 8-year-old boys. Eur J Clin Nutr. 2005;59(3):393-8. [Crossref]  [PubMed] 
  52. Torfadottir JE, Steingrimsdottir L, Mucci L, Aspelund T, Kasperzyk JL, Olafsson O, et al. Milk intake in early life and risk of advanced prostate cancer. Am J Epidemiol. 2012;175(2):144-53. [Crossref]  [PubMed]  [PMC] 
  53. Parkin DM. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011;105 Suppl 2:S2-5. [Crossref]  [PubMed]  [PMC] 
  54. Malekinejad H, Scherpenisse P, Bergwerff AA. Naturally occurring estrogens in processed milk and in raw milk (from gestated cows). J Agric Food Chem. 2006;54(26):9785-91. [Crossref]  [PubMed] 
  55. Farlow DW, Xu X, Veenstra TD. Quantitative measurement of endogenous estrogen metabolites, risk-factors for development of breast cancer, in commercial milk products by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(13):1327-34. [Crossref]  [PubMed] 
  56. Danby FW. Acne, dairy and cancer: the 5alpha-P link. Dermatoendocrinol. 2009;1(1):12-6. [Crossref]  [PubMed]  [PMC] 
  57. Maruyama K, Oshima T, Ohyama K. Exposure to exogenous estrogen through intake of commercial milk produced from pregnant cows. Pediatr Int. 2010;52(1):33-8. [Crossref]  [PubMed] 
  58. Norat T, Vieira AR, Chan D, Aune D, Abar L, Navarro D, et al. World Cancer Research Fund International Systematic Literature Review. The Associations between Food, Nutrition and Physical Activity and the Risk of Prostate Cancer; 2014. p.181. Available from: https://www.wcrf.org/sites/default/files/prostate-cancer-slr.pdf Accessed April 14,2019.

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com